Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
follitropin (Merck KGaA)
- Development stage
- Approved
- Lead developer
- Merck KGaA
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intramuscular
01
Overview
Follitropin is a recombinant form of human follicle-stimulating hormone (FSH), a glycoprotein hormone produced by the anterior pituitary gland. It is used primarily to stimulate ovarian follicular development in women with primary ovarian hypogonadism and to induce spermatogenesis in men with hypogonadotropic hypogonadism. Recombinant follitropins are manufactured using DNA technology and are available as several variants (follitropin alfa, beta, delta), which differ slightly in glycosylation patterns but share the same amino acid sequence. The drug acts by binding to the Follicle-stimulating hormone receptor (FSHR) on granulosa cells of the ovary or Sertoli cells of the testis and activating cAMP-mediated signaling pathways that promote gametogenesis[1][5][8]. Primary indications include infertility treatment for anovulatory women and controlled ovarian stimulation for assisted reproductive technologies such as IVF[2][5].
- Brand names
- Gonal-fFollistimFollistim AQPuregonBemfolaOvaleapPergoveris
- Other names
- recombinant human follicle-stimulating hormoner-hFSH
02
Targets
FSHR (Follicle-stimulating hormone receptor)
Beyond the preview
Go deeper on follitropin (Merck KGaA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on follitropin (Merck KGaA).